CNSP
Income statement / Annual
Last year (2024), CNS Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, CNS Pharmaceuticals, Inc.'s net income was -$14.86 M.
See CNS Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$4,134.00
|
$11,756.00
|
$13,070.00
|
$11,096.00
|
$1,955.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$4,134.00
|
-$11,756.00
|
-$13,070.00
|
-$11,096.00
|
-$1,955.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.29 M
|
$14.10 M
|
$9.30 M
|
$9.35 M
|
$5.06 M
|
$1.85 M
|
$21,267.00
|
$32,638.00
|
| General & Administrative Expenses |
$5.61 M
|
$4.77 M
|
$5.97 M
|
$4.68 M
|
$4.39 M
|
$1.98 M
|
$860,520.00
|
$437,921.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$255,454.00
|
| Selling, General & Administrative Expenses |
$5.61 M
|
$4.77 M
|
$5.97 M
|
$4.68 M
|
$4.39 M
|
$1.98 M
|
$860,520.00
|
$182,467.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$6.46 M
|
$0.00
|
| Operating Expenses |
$14.90 M
|
$18.87 M
|
$15.27 M
|
$14.03 M
|
$9.45 M
|
$3.83 M
|
$881,787.00
|
$215,105.00
|
| Cost And Expenses |
$0.00
|
$18.87 M
|
$15.27 M
|
$14.03 M
|
$9.45 M
|
$3.83 M
|
$881,787.00
|
$215,105.00
|
| Interest Income |
$60,262.00
|
$13,882.00
|
$7.03
|
$9.29
|
$3.26
|
$44.23
|
$0.00
|
$10,217.00
|
| Interest Expense |
-$16,120.00
|
$0.00
|
$7,027.00
|
$9,285.00
|
$3,264.00
|
$44,234.00
|
$46,697.00
|
$0.00
|
| Depreciation & Amortization |
-$28,022.00
|
$4,134.00
|
$11,756.00
|
$13,070.00
|
$11,096.00
|
$1,955.00
|
$881,787.00
|
$516,252.00
|
| EBITDA |
-$14.90 M |
-$18.86 M |
-$15.26 M |
-$14.47 M |
-$9.44 M |
-$3.83 M |
-$6.46 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$44,142.00
|
$13,882.00
|
-$7,027.00
|
-$9,285.00
|
-$3,264.00
|
-$44,234.00
|
-$6.51 M
|
-$4,262.00
|
| Income Before Tax |
-$14.86 M
|
-$18.85 M
|
-$15.27 M
|
-$14.04 M
|
-$9.46 M
|
-$3.88 M
|
-$7.39 M
|
-$219,362.00
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$7,027.00
|
$9,285.00
|
$3,264.00
|
$42,279.00
|
$46,697.00
|
-$516,252.00
|
| Net Income |
-$14.86 M
|
-$18.85 M
|
-$15.27 M
|
-$14.50 M
|
-$9.46 M
|
-$3.88 M
|
-$7.39 M
|
-$526,469.00
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-38.87 |
-251.35 |
-560.83 |
-852.66 |
-859.81 |
-353.57 |
-674.07 |
-48.01 |
| EPS Diluted |
-38.87 |
-250.19 |
-560.83 |
-825.04 |
-853.68 |
-353.57 |
-674.07 |
-48.01 |
| Weighted Average Shares Out |
$382,241.00
|
$75,000.00
|
$27.24 M
|
$17.00 M
|
$11.00 M
|
$10.97 M
|
$10.97 M
|
$10.97 M
|
| Weighted Average Shares Out Diluted |
$382,241.00
|
$75,347.00
|
$27.24 M
|
$17.57 M
|
$11.08 M
|
$10.97 M
|
$10.97 M
|
$10.97 M
|
| Link |
|
|
|
|
|
|
|
|
